The demand for experienced professionals is far outpacing supply, with firms aggressively poaching from banks, brokerages and ...

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at ABOUT TG THERAPEUTICS TG Therapeutics is a fully ...

Breakthrough audio system features Xspace™ spatial audio engine, wireless neck speaker for 5.1.2 surround, wireless modular ...

Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant's Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib ...

Event Takes Place Nov. 15-16 at Globe Life Park in Arlington, Texas; Modus’ Revolutionary 48V Audio System Technology Marks a Significant Advancement in Mobile Audio Integration with Electric Vehicles ...

GovHost, a leading provider of public safety software solutions, today announced its acquisition of True North Software LLC, an Illinois-based company known for its cloud-native Computer-Aided ...

Findings showed fenebrutinib significantly reduced relapses vs teriflunomide in RMS and was noninferior to ocrelizumab in slowing disability progression in PPMS. Topline data were announced from two ...

Roche (RHHBY) stock gains and TG Therapeutics (TGTX) stock falls as the Swiss firm's new drug for multiple sclerosis succeeds in two late-stage trials. Read more here.

May 7th, 1915. The RMS Lusitania sliced through calm Atlantic waters, unaware that German U-boat U-20 was waiting. When a ...

Hannover Re will book a loss from Hurricane Melissa in the hundreds of millions of euros due to a higher-than-average market ...

Lockheed Martin delivered solid third-quarter 2025 results, reporting sales of $18.6 billion compared to $17.1 billion in the same period last year, representing a 9% year-over-year increase. Sould ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the first Phase III (FENhance 2) of two pivotal, similarly-designed Phase III studies (FENhance 1 and 2) in ...